Barclays
RKDA icon

Barclays’s Arcadia Biosciences RKDA Stock Holding History

Barclays’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-25
Closed -$24K – 7232
2018
Q1 		$24K Buy
+25
New +$11.2K ﹤0.01% 6358
2016
Q3 		– Sell
-7
Closed -$14K – 6764
2016
Q2 		$14K Buy
+7
New +$11.7K ﹤0.01% 5428
2015
Q4 		– Hold
0
– – – 6474
2015
Q3 		– Hold
0
– – – 7008
2015
Q2 		– Hold
0
– – – 6930

Other funds holding RKDA

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's RKDA Position: Q2 2018 in Review

Barclays sold out of Arcadia Biosciences (RKDA) in Q2 2018, closing a stake of 25 shares — an estimated $24K sold.

Barclays first reported a position in RKDA in Q2 2016 and held it in 2 quarters. The position peaked at $24K in Q1 2018. 13 funds tracked by Wall St. Rank hold RKDA as of Q2 2018.

  • Barclays reported no remaining Arcadia Biosciences position as of Q2 2018 after selling out during the quarter.
  • Barclays sold 25 Arcadia Biosciences shares in Q2 2018, an estimated $24K.
  • Barclays first reported a position in Arcadia Biosciences in Q2 2016 and held it in 2 quarters.
  • Barclays's Arcadia Biosciences position peaked at $24K in Q1 2018.
  • 13 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q2 2018.

Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.